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therapy is used, between -$7.9 and $68.8 million in El
Salvador, and between -$888.8 thousand and $8.6
million in Belize. 
CONCLUSIONS: Since the ratio of antiretroviral drug
costs to GDP was 0.041% in Brazil in 2000, these three
Central American countries may have more difﬁculty
affording antiretroviral therapy unless double combina-
tion therapy is used.
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OBJECTIVE: An issue that has recently received atten-
tion from health economists is how to handle the problem
of missing data in stochastic cost-effectiveness analysis.
The purpose of this paper is to highlight the impact 
that different approaches to the imputation of missing
data can have on estimates of the physical quantities of
medical care resource use. 
METHODS: Medical care resource use data were 
collected prospectively in a 6-month RCT comparing 
two treatments for a chronic condition that is charac-
terised by acute episodes. Two approaches of the 
multiple imputation were used to address the problem of
missing data. Method A relied on imputing missing data
for total costs and then estimating the physical quantities
of medical care resource use. Method B relied on imput-
ing missing data for the physical quantities of medical
care resource use and then estimating total costs. Results
for physician and nurse visits and days in the hospital
were reported. 
RESULTS: The two multiple imputation approaches 
produced different estimates of medical care resource use.
For method A, the average number of physician and nurse
visits and days in the hospital between the two groups
were 5.7 vs. 5.3 physician visits, 1.0 vs. 0.9 nurse visits,
and 4.0 vs. 4.7 days in the hospital. For method B the
average number of physician and nurse visits and days 
in the hospital between the two groups were 6.0 vs. 6.3
physician visits, 1.2 vs. 1.3 nurse visits, and 4.0 vs. 5.0
days in the hospital. 
CONCLUSIONS: Medical care resource use estimates are
sensitive to the imputation approach. Method B builds
prediction models speciﬁcally for the utilisation compo-
nents under the imputation and results from the imputed
datasets are believed to be less biased. It also provides
more ﬂexibility for analysing the cost components.
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The US Public Health Service Panel on Cost-Effectiveness
issued a series of recommendations designed to improve
the rigor and consistency of cost-effectiveness analyses.
While the Panel’s individual recommendations are largely
sound, they nevertheless vary in importance. That is, the
violation of some recommendations will yield dramati-
cally different cost-effectiveness estimates and resource
allocation decisions than the violation of other 
recommendations. 
OBJECTIVE: The Panel has advocated the use of quality-
adjusted life-years (QALYs) as the best way to evaluate
outcomes in a cost-effectiveness analysis. We consider the
importance of this recommendation for cancer preven-
tion, screening, and treatment by studying the empirical
relationship between cost/life-year and cost/QALY. In
addition, we consider whether adjusting for health-
related quality of life (QOL) affects the ultimate resource
allocation decision implied by the cost-effectiveness ratio. 
METHODS: We identiﬁed 198 articles reporting two 
or more outcome measures for the same intervention:
cost/life-year, cost/QALY, total life-years, total QALYs,
incremental life-years, or incremental QALYs. We calcu-
lated a correlation matrix for these outcomes and per-
formed a regression analysis to examine the relationship
between cost/life-year and cost/QALY. We also employed
various willingness to pay (WTP) thresholds to assess
whether the use of cost/life-year would yield different
resource allocation decisions than cost/QALY. 
RESULTS: The correlation between the total life-years
and total QALYs associated with the intervention is 0.97
(P < 0.0001). The correlation between cost/life-year and
cost/QALY is 0.78 (P < 0.0001). Assuming a $50,000
WTP threshold, adjustment for QOL would affect choice
in 7% of cases. With a $400,000 threshold, QOL would
affect choice in 2% of cases. 
CONCLUSION: The outcome measures of life-years and
QALYs are highly correlated with one another. While
adjusting for QOL can make an important difference 
in some economic analyses, it generally does not affect
implied resource allocation decisions for cancer preven-
tion, screening, and treatment.
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OBJECTIVES: Most health economic models assessing
policies for screening for diabetic nephropathy assume
100% sensitivity and speciﬁcity of screening methods. We
tested the impact considering these factors on cost-
effectiveness of screening for diabetic nephropathy in type
2 diabetes. 
METHODS: A Markov model simulated the progression
of patients from no renal disease, to microalbuminuria
(MAU), to gross proteinuria, and eventually to renal
failure. Data were derived from published sources. Costs
and life expectancy (LE) (discounted at 3% p.a.) and
incremental costs/life year gained (C/LYG) were calcu-
lated for an MAU screening program (treating with ACE
inhibitors if detected) versus no screening assuming 100%
sensitivity and speciﬁcity of the screening method 
(scenario 1), and were compared to those calculated with
more realistic values of sensitivity 71% and speciﬁcity
98% (scenario 2). A US Medicare perspective was taken. 
RESULTS: Costs and LE in a typical type 2 population
for scenario 1 were: $7,047 and 12.70 years in the
screened population, and $11,465 and 12.43 years in the
unscreened population, with screening reducing overall
costs and increasing life expectancy. For scenario 2, costs
and LE in the screened population were $7,303 and 12.66
years, (and remained unchanged in the unscreened popu-
lation). Sensitivity analysis of the sensitivity of screening
showed that at sensitivities below 50%, LE and costs
exponentially approached those of the no screening 
strategy. 
CONCLUSIONS: While affecting the absolute values 
for costs and LE, more realist assumptions about the 
sensitivity and speciﬁcity of screening methods for
nephropathy had little impact on the relative results, 
with a nephropathy screening program dominant to no
screening under both sets of assumption. If sensitivity of
a nephropathy screening test is <50%, sensitivity should
be incorporated in future nephropathy health economic
models assessing screening intervention policies.
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OBJECTIVES: To determine the impact of ignoring 
population heterogeneity when Markov models are used
to estimate cost effectiveness ratios. 
METHODS: We constructed a simple Markov model
with three health states: healthy, sick, and dead. We
modeled heterogeneity by assuming that there are two
risk groups (high- and low-risk) differentiated by their
probability of getting sick. We used the Markov model to
estimate the incremental cost effectiveness ratio (ICER) of
a medical intervention that reduces the probability of
becoming sick among high-risk individuals but cannot be
targeted to a single risk group. We used two methods to
estimate the ICER for the intervention: 1. pooling the two
risk groups together into a single homogeneous popula-
tion group; and 2. analyzing the two heterogeneous
groups separately. 
RESULTS: We prove algebraically that the pooled model
always overestimates the number of quality adjusted life
years of survival (QALYs) gained as a result of a medical
intervention. The pooled model may overestimate or
underestimate the incremental costs depending on the
relationships between several parameter values. Thus, 
the pooled model may overestimate or underestimate the
ICER of an intervention. If all costs vary directly in the
amount of time spent in each health state, then both
methods always yield the same ICER. These results can
be extended to Markov models with more than three
health states. 
CONCLUSIONS: Ignoring heterogeneity may lead to
erroneous ICER estimates when Markov models are used
to represent disease progression. Since the sign of the
error depends on several parameters it may be difﬁcult 
to interpret comparisons of the results of modeling
studies. These problems may not be alleviated by 
selecting conservative parameter estimates. The simplify-
ing assumption of combining heterogeneous population
groups should thus be avoided. Policy makers should be
aware of these results when interpreting ICERs estimated
using Markov models.
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OBJECTIVE: The number needed to treat to achieve 
the mortality beneﬁt of HMG-CoA reductase inhibitors
(statins) is substantially lower for secondary prevention
populations when compared to primary prevention 
populations. To determine whether patients with “most
to gain” are more compliant, we compared statin com-
pliance in primary and secondary prevention populations
in a midwestern managed care organization. 
METHODS: Non-Medicaid MCO enrollees who ﬁlled 
≥2 statin prescriptions from January 1998 to November
2001 were included. Administrative data classiﬁed
patients as secondary prevention (diagnosis of AMI or
had undergone PTCA or CABG) or primary prevention
(all others). Compliance was assessed by quantifying the
number of days without medication (cumulative multiple
reﬁll-interval gap [CMG]) for 2 periods: 1) while actively
taking statin (until last ﬁlled prescription ends), and 2)
